Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma
Dai Ogata(Unknown), Tetsuya Tsuchida(Saitama Medical University), Naoya Yamazaki(Tokyo National Hospital), Kohei Oashi(Saitama Cancer Center), Kenji Suzuki(Saitama Medical University), Hiroto Yanagisawa(Saitama Medical University)
Cited by 39
Related Papers
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338